Media coverage about Advaxis (NASDAQ:ADXS) has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Advaxis earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 44.9814478573516 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
ADXS has been the topic of a number of recent research reports. BidaskClub upgraded Advaxis from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research report on Friday, September 15th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $19.00 price objective on shares of Advaxis in a research report on Monday, September 25th.
Shares of Advaxis (NASDAQ ADXS) opened at $3.04 on Friday. Advaxis has a 52-week low of $2.83 and a 52-week high of $10.06.
In other Advaxis news, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the company’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $4.42, for a total value of $5,477,807.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Robert Petit sold 12,625 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the sale, the insider now owns 237,265 shares in the company, valued at approximately $756,875.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,872,291 shares of company stock worth $8,163,810. Insiders own 7.21% of the company’s stock.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.